Título :	Multiple sclerosis therapeutics
Tipo de documento:	texto impreso
Autores:	Jeffrey A. Cohen, Editor científico ; Richard A. Rudick, Autor
Mención de edición:	4a ed
Editorial:	New York : Cambridge University Press
Fecha de publicación:	2011
Número de páginas:	xvii, 752 p
Il.:	il. col. byn.
Dimensiones:	Pasta dura
ISBN/ISSN/DL:	978-0-521-76627-2
Nota general:	Incluye Referencias bibliográficas e índice
Idioma :	Inglés (eng)
Palabras clave:	ESCLEROSIS MÚLTIPLE, ESCLEROSIS MÚLTIPLE-PATOLOGÍA, ESCLEROSIS MÚLTIPLE-TERAPIA, CUIDADO DE LA SALUD
Clasificación:	616.834 - Enfermedades - Enfermedades del sistema nervioso y trastornos mentales – Otras enfermedades orgánicas del sistema nervioso central – Esclerosis múltiple
Nota de contenido:	Contenido: 1. Aspects of multiple sclerosis that relate to experimental therapeutics. // 2. The pathology of multiple sclerosis. // 3. The immunology of multiple sclerosis. // 4 The genetics of multiple sclerosis. // 5 The epidemiology of multiple sclerosis. // Section II – Clinical trial methodology. // 6 Measures of neurological impairment and disability in multiple sclerosis. // 7 Assessment of neuropsychological function in multiple sclerosis. // 8 Health-related quality of life assessment in multiple sclerosis. // 9 Measures of acute and chronic lesions visualized by conventional magnetic resonance imaging. // 10 Measures of magnetization transfer. // 11 Measurement of CNS atrophy. // 12 Axonal pathology in patients with multiple sclerosis: Evidence from in vivo proton. // 13 Imaging of gray matter lesions in multiple sclerosis. // 14 Functional imaging in multiple sclerosis. // 15 Diffusion imaging in multiple sclerosis. // 16 The use of MRI in multiple sclerosis clinical trials. // 17 Optical coherence tomography to monitor axonal and neuronal integrity in multiple sclerosis. // 18 The process of drug development and approval in the United States, the European Union, and Asia. // 19 Selection, interpretation, and development of end-points in multiple sclerosis clinical trials. // 20 The challenge of demonstrating long-term benefit of disease-modifying therapies in multiple sclerosis. // 21 The growing need for alternative clinical trial designs for multiple sclerosis. // 22 Ethical considerations in multiple sclerosis clinical trials. // 23 Pharmacogenomics and related discovery-driven approaches in multiple sclerosis. // 24 Neutralizing antibodies directed against biologic agents to treat multiple sclerosis. // Section III – Clinical trialsof multiple sclerosis therapies. // 25 Interferon beta to treat multiple sclerosis. // 26 Glatiramer acetate to treat multiple sclerosis. // 27 Natalizumab to treat multiple sclerosis. // 28 Mitoxantrone to treat multiple sclerosis. // 29 Cladribine to treat multiple sclerosis. // 30 Fingolimod to treat multiple sclerosis. // 31 Dimethyl fumarate to treat multiple sclerosis. // 32 Alemtuzumab to treat multiple sclerosis. // 33 Daclizumab to treat multiple sclerosis. // 34 Laquinimod to treat multiple sclerosis. // 35 Teriflunomide to treat multiple sclerosis. // 36 High-dose methylprednisolone to treat multiple sclerosis. // 37 Use of immunosuppressants to treat multiple sclerosis. // 38 Intravenous immunoglobulin to treat multiple sclerosis. // 39 Plasma exchange treatment for CNS inflammatory demyelinating disease. // 40 Statins in multiple sclerosis. // 41 T-cell-based therapies for multiple. // 42 B-cell-based therapies for multiple. // 43 Sex hormones and other pregnancy-related factors with therapeutic potential in multiple sclerosis. // 44 Hematopoietic stem cell transplantation to treat multiple sclerosis. // 45 Mesenchymal stem cell transplantation to treat multiple sclerosis // 46 Neuroprotection in multiple sclerosis. // 47 Combination therapy in multiple sclerosis. // 48 Dalfampridine in multiple sclerosis. // 49 Complementary and alternative treatments in multiple sclerosis. // 50 The role of chronic cerebrospinal venous insufficiency in multiple sclerosis. // 51 Disease-modifying therapy for multiple sclerosis in clinical practice. // 52 Treatment for patients with primary progressive multiple sclerosis. // 53 Diagnosis, pathogenesis, and treatment of neuromyelitis optica (NMO) spectrum disorders. // 54 Management of pediatric multiple sclerosis. // 55 Use of MRI in the clinical management of multiple sclerosis. // 56 Multiple sclerosis-associated fatigue. // 57 Management of spasticity. // 58 Management of bladder and sexual dysfunction in multiple sclerosis. // 59 Depression in multiple sclerosis. // 60 Assessment and treatment of pain disorders in multiple sclerosis. // 61 Management of medical comorbidities in patients with multiple sclerosis. // 62 Rehabilitation in multiple sclerosis.

Multiple sclerosis therapeutics [texto impreso] / Jeffrey A. Cohen, Editor científico ; Richard A. Rudick, Autor  . -  4a ed . - New York : Cambridge University Press, 2011 . - xvii, 752 p : il. col. byn. ; Pasta dura.
ISBN : 978-0-521-76627-2
Incluye Referencias bibliográficas e índice
Idioma : Inglés (eng)

Palabras clave:	ESCLEROSIS MÚLTIPLE, ESCLEROSIS MÚLTIPLE-PATOLOGÍA, ESCLEROSIS MÚLTIPLE-TERAPIA, CUIDADO DE LA SALUD
Clasificación:	616.834 - Enfermedades - Enfermedades del sistema nervioso y trastornos mentales – Otras enfermedades orgánicas del sistema nervioso central – Esclerosis múltiple
Nota de contenido:	Contenido: 1. Aspects of multiple sclerosis that relate to experimental therapeutics. // 2. The pathology of multiple sclerosis. // 3. The immunology of multiple sclerosis. // 4 The genetics of multiple sclerosis. // 5 The epidemiology of multiple sclerosis. // Section II – Clinical trial methodology. // 6 Measures of neurological impairment and disability in multiple sclerosis. // 7 Assessment of neuropsychological function in multiple sclerosis. // 8 Health-related quality of life assessment in multiple sclerosis. // 9 Measures of acute and chronic lesions visualized by conventional magnetic resonance imaging. // 10 Measures of magnetization transfer. // 11 Measurement of CNS atrophy. // 12 Axonal pathology in patients with multiple sclerosis: Evidence from in vivo proton. // 13 Imaging of gray matter lesions in multiple sclerosis. // 14 Functional imaging in multiple sclerosis. // 15 Diffusion imaging in multiple sclerosis. // 16 The use of MRI in multiple sclerosis clinical trials. // 17 Optical coherence tomography to monitor axonal and neuronal integrity in multiple sclerosis. // 18 The process of drug development and approval in the United States, the European Union, and Asia. // 19 Selection, interpretation, and development of end-points in multiple sclerosis clinical trials. // 20 The challenge of demonstrating long-term benefit of disease-modifying therapies in multiple sclerosis. // 21 The growing need for alternative clinical trial designs for multiple sclerosis. // 22 Ethical considerations in multiple sclerosis clinical trials. // 23 Pharmacogenomics and related discovery-driven approaches in multiple sclerosis. // 24 Neutralizing antibodies directed against biologic agents to treat multiple sclerosis. // Section III – Clinical trialsof multiple sclerosis therapies. // 25 Interferon beta to treat multiple sclerosis. // 26 Glatiramer acetate to treat multiple sclerosis. // 27 Natalizumab to treat multiple sclerosis. // 28 Mitoxantrone to treat multiple sclerosis. // 29 Cladribine to treat multiple sclerosis. // 30 Fingolimod to treat multiple sclerosis. // 31 Dimethyl fumarate to treat multiple sclerosis. // 32 Alemtuzumab to treat multiple sclerosis. // 33 Daclizumab to treat multiple sclerosis. // 34 Laquinimod to treat multiple sclerosis. // 35 Teriflunomide to treat multiple sclerosis. // 36 High-dose methylprednisolone to treat multiple sclerosis. // 37 Use of immunosuppressants to treat multiple sclerosis. // 38 Intravenous immunoglobulin to treat multiple sclerosis. // 39 Plasma exchange treatment for CNS inflammatory demyelinating disease. // 40 Statins in multiple sclerosis. // 41 T-cell-based therapies for multiple. // 42 B-cell-based therapies for multiple. // 43 Sex hormones and other pregnancy-related factors with therapeutic potential in multiple sclerosis. // 44 Hematopoietic stem cell transplantation to treat multiple sclerosis. // 45 Mesenchymal stem cell transplantation to treat multiple sclerosis // 46 Neuroprotection in multiple sclerosis. // 47 Combination therapy in multiple sclerosis. // 48 Dalfampridine in multiple sclerosis. // 49 Complementary and alternative treatments in multiple sclerosis. // 50 The role of chronic cerebrospinal venous insufficiency in multiple sclerosis. // 51 Disease-modifying therapy for multiple sclerosis in clinical practice. // 52 Treatment for patients with primary progressive multiple sclerosis. // 53 Diagnosis, pathogenesis, and treatment of neuromyelitis optica (NMO) spectrum disorders. // 54 Management of pediatric multiple sclerosis. // 55 Use of MRI in the clinical management of multiple sclerosis. // 56 Multiple sclerosis-associated fatigue. // 57 Management of spasticity. // 58 Management of bladder and sexual dysfunction in multiple sclerosis. // 59 Depression in multiple sclerosis. // 60 Assessment and treatment of pain disorders in multiple sclerosis. // 61 Management of medical comorbidities in patients with multiple sclerosis. // 62 Rehabilitation in multiple sclerosis.